Bank Of New York Mellon Corp Arcus Biosciences, Inc. Transaction History

Bank Of New York Mellon Corp

$538 Trillion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$15.96 - $23.15 $7.64 Million - $11.1 Million	478,400 New	478,400 $8.73 Billion
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $9.62 Million - $17.4 Million	488,451 New	488,451 $10.1 Million
Q3 2022 Nov 14, 2022	BUY	$23.23 - $30.07 $1.1 Million - $1.42 Million	47,247 Added 11.16%	470,696 $12.3 Million
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $3.66 Million - $8.02 Million	212,614 Added 100.84%	423,449 $10.7 Million
Q1 2022 May 11, 2022	SELL	$28.92 - $41.83 $845,302 - $1.22 Million	-29,229 Reduced 12.18%	210,835 $6.65 Million
Q4 2021 Feb 11, 2022	BUY	$31.38 - $48.47 $617,275 - $953,453	19,671 Added 8.93%	240,064 $9.72 Million
Q3 2021 Nov 12, 2021	BUY	$26.93 - $37.68 $457,325 - $639,881	16,982 Added 8.35%	220,393 $7.69 Million
Q2 2021 Aug 11, 2021	BUY	$22.75 - $35.77 $765,810 - $1.2 Million	33,662 Added 19.83%	203,411 $5.59 Million
Q1 2021 May 13, 2021	SELL	$26.16 - $41.39 $335,214 - $530,371	-12,814 Reduced 7.02%	169,749 $4.77 Million
Q4 2020 Feb 09, 2021	BUY	$17.0 - $32.36 $322,422 - $613,739	18,966 Added 11.59%	182,563 $4.74 Million
Q3 2020 Nov 12, 2020	SELL	$17.14 - $25.47 $99,309 - $147,573	-5,794 Reduced 3.42%	163,597 $2.8 Million
Q2 2020 Aug 12, 2020	BUY	$13.97 - $36.56 $281,453 - $736,574	20,147 Added 13.5%	169,391 $4.19 Million
Q1 2020 May 06, 2020	BUY	$8.78 - $19.28 $212,291 - $466,171	24,179 Added 19.33%	149,244 $2.07 Million
Q4 2019 Feb 14, 2020	BUY	$7.33 - $10.79 $1,033 - $1,521	141 Added 0.11%	125,065 $1.26 Million
Q3 2019 Nov 07, 2019	BUY	$6.44 - $10.18 $51,140 - $80,839	7,941 Added 6.79%	124,924 $1.14 Million
Q2 2019 Aug 12, 2019	BUY	$7.29 - $13.38 $72,754 - $133,532	9,980 Added 9.33%	116,983 $930,000
Q1 2019 May 14, 2019	BUY	$8.95 - $12.49 $60,555 - $84,507	6,766 Added 6.75%	107,003 $1.34 Million
Q4 2018 Feb 11, 2019	BUY	$9.74 - $14.5 $769,966 - $1.15 Million	79,052 Added 373.15%	100,237 $1.08 Million
Q3 2018 Nov 09, 2018	BUY	$10.88 - $14.95 $55,901 - $76,813	5,138 Added 32.02%	21,185 $0
Q2 2018 Aug 06, 2018	BUY	$12.24 - $17.05 $196,415 - $273,601	16,047 New	16,047 $196,000

Others Institutions Holding RCUS

# of Institutions

200

Shares Held

51.5M

Call Options Held

236K

Put Options Held

141K

Black Rock Inc. New York, NY

9.76M
Shares

$128 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

5.47M
Shares

$72 Million
0.0% of portfolio
Woodline Partners LP San Francisco, CA

3.48M
Shares

$45.8 Million
0.48% of portfolio
State Street Corp Boston, MA

3.01M
Shares

$39.6 Million
0.0% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

2.44M
Shares

$32.1 Million
0.1% of portfolio

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account